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Abstract  
Aim: To identify clinical and molecular prognostic factors in differentiated 
thyroid cancer (DTC) 
Methods: A web based longitudinal database of newly diagnosed DTC was 
settled down. The risk of recurrence and the response to treatment were 
classified according to the American Thyroid Association (ATA) guidelines. 
Circulating miR analysis of sera collected before surgery and about 1 months and 
1-2 years after surgery was performed with TaqMan MicroRNA Assay.  
Results: 2730 patients had a follow-up ≥1 year. The ATA risk of recurrence was 
low in 1386 (50.8%), intermediate in 1168 (42.8%) and high in 176 (6.4%). The 
response to treatment was excellent in 1675 (61.3%), biochemical incomplete in 
63 (2.3%), structural incomplete in 70 (2.6%), and indeterminate in  922 
(33.8%). A significantly higher rate of structural disease was found in 
intermediate (2.7%, Odds ratio 4.85, 95% confidence interval 2.18 - 12.23, 
p<0.01) and high risk (17.1% Odds ratio 35.21, 95% confidence interval 15.41 - 
90.66, p<0.01) patients compared with low risk patients (0.6%). Of the 829 
patients that had a follow up of ≥3 years, only 3 (0.6%) intermediate risk patients 
experienced relapse.  
Serum samples of 44 patients with papillary thyroid cancer (PTC) were available 
for miR profiling. After a screening analysis, miR-146a-5p and miR-221-3p were 
selected for validation because of superior accuracy in PTC identification from 
healthy controls and benign thyroid nodules. The trend over time of miR-146a-
5p and miR-221-3p was decreasing in patients with disease remission and 
increasing in patients with structural disease. In 3 cases miR profile was more 
informative than the serum thyroglobulin.  
Conclusion: The ATA risk stratification is an effective clinical prognostic tool for 
structural disease prediction in DTC. One third of the patients has an 
indeterminate response to treatment due to low detectable serum markers 
(thyroglobulin or anti thyroglobulin antibodies). miR profile may represents a 
promising alternative marker of disease status for these patients.    
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INTRODUCTION 
 
Thyroid cancer 
Thyroid cancer is the most frequent endocrine malignancy. It represents the 3% 
of all new cancer diagnoses, according to the data collected form the 
Surveillance, Epidemiology and End Results (SEER) program 
(https://seer.cancer.gov/statfacts/html/thyro.html last accessed 09 December 
2018). The 96% of all thyroid cancers originates from follicular cells, and of these, 
99% are differentiated thyroid cancer (DTC) and 1% are anaplastic thyroid 
cancers. DTCs are classified as papillary (PTC, 95%), follicular (FTC), Hürthle cell 
carcinoma (HCC) and poorly differentiated thyroid cancers (PDTCs) (5%) (Fagin 
and Wells 2016). Medullary thyroid carcinoma is rare, representing <3% of all 
thyroid cancers and originates from parafollicular cells (also known as C cells).  
DTCs incidence has increased over the past three decades by >5% per year to 
reach 14 cases per 100,000 persons per year (Davies and Welch 2014). 
Overdiagnosis plays a relevant role in this incidence increase but is not possible 
to exclude the role of environmental risk factors, such as radiation exposure and 
obesity (Vaccarella, Dal Maso et al. 2015) (Grani, Lamartina et al. 2018).  
Thyroid cancers have a global mortality at 5 years of less than 2% (SEER). Patients 
with advanced disease with increased risk of disease specific death are the 
minority (Milano 2018). The incidence-based mortality of PTCs increased by 
1.1% per year during 1994–2013 (from 0.40 per 100,000 person-years in 1994–
1997 to 0.46 per 100,000 person-years in 2010–2013). Over the same time 
period, the incidence-based mortality of PTCs with distant metastases increased 
by 2.9% per year (Lim, Devesa et al. 2017).  
The one-size-fits-all treatment paradigm for DTCs used to consist the near-
universal use of total thyroidectomy and radioactive iodine remnant ablation 
followed by TSH- suppressive therapy with levothyroxine (Cabanillas, McFadden 
et al. 2016). High risk DTCs are likely to benefit from such an aggressive 
approach. Nevertheless, the vast majority of DTCs in contemporary series are at 
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low risk of recurrence for whom a less aggressive and more individualized 
approach is appropriate. Management options now include active surveillance 
for select very low-risk tumors (Ito, Miyauchi et al. 2010, Tuttle, Fagin et al. 2017) 
and less extensive surgical treatment (Adam, Pura et al. 2015) (e.g. total 
thyroidectomy with no prophylactic lymph node dissection or thyroid lobectomy 
alone) for low and selected intermediate-risk tumors. Selective use of 
radioiodine remnant ablation is also advised (Lamartina, Durante et al. 2015, 
Lamartina, Durante et al. 2017). Also, the aims and drawbacks of levothyroxine 
treatment (notably the risks of long-term TSH suppression, which is now 
restricted to patients with persistent disease) are being redefined (Biondi and 
Cooper 2010, Lamartina, Montesano et al. 2018).  
This paradigm shift was driven by the increased awareness on DTC patient’s 
outcome and the availability of accurate diagnostic tools, less influenced by the 
presence of some amounts of normal thyroid tissue.  
Most DTC patients have no evidence of disease after initial treatment, and 
recurrence, that is localized in the neck in the vast majority of cases, is highly 
unlikely in these cases (<1% in patients who are at low risk) (Durante, Attard et 
al. 2010, Schlumberger, Leboulleux et al. 2018). In terms of healthcare resources, 
the cost of low risk DTC follow up is 6–7 times higher than the cost of patients 
with an intermediate risk and high risk of recurrence (Wang, Roman et al. 2015). 
The proportion of patients who have a low risk of recurrence is high (about 2/3 
of the patients) in contemporary prospective series (Lamartina, Durante et al. 
2017). Appropriate risk stratification tools and predictive biomarkers are 
therefore crucial for the optimization of thyroid cancer follow up. 
 
Tools for risk stratification  
Risk of death from thyroid cancer  
The American Joint Committee on Cancer and Union Internationale Contre le 
Cancer (AJCC/UICC) tumor node metastasis (TNM) staging system is the most 
diffused system for tumor death risk estimate used in clinical practice (Tuttle, 
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Haugen et al. 2017). The 8th edition of AJCC/UICC TNM system (published in 
2017), introduced several changes aimed to improve the identification of the 
small subset of patients that have a substantial risk of thyroid cancer death. 
AJCC/UICC TNM 7th and 8th edition are summarized in Table 1. 
Unlikely other tumors, age is a crucial risk factor of thyroid cancer death, the risk 
increases in a continuous fashion with increasing age but fixed cut off have been 
introduced to render the scores simpler in everyday clinical practice (Nixon, 
Wang et al. 2016, Tuttle, Haugen et al. 2017). In thyroid cancer staging the 
patients below the age cutoff are classified only according to the absence (stage 
I) or the presence of distant metastases (stage II). The first important change 
made in the 8th edition AJCC/UICC TNM staging system, was increasing the age 
threshold from 45 to 55 years. As a consequence, a larger proportion of patients 
will be classified as stage I or II based only on the absence or the presence of 
distant metastases, respectively (Lamartina, Grani et al. 2017). Another change 
in the 8th edition of the staging system is that tumors are no longer classified as 
T3 solely because they are associated with microscopic extrathyroidal extension 
to the perithyroidal soft tissues; such tumors are now classified only according 
to tumor size. Tumors with lymph node metastases in the central and lateral 
compartments have also been downgraded to stage II. The adoption of the 8th 
edition of the tumor node metastasis system is expected to result in the down-
staging of approximately one-third of patients with DTC: most will be classified 
as stage I or II, while only a minority (5-10%) will fall in stage III and IV (Lamartina, 
Grani et al. 2017). A better prediction of  disease-related mortality with 
AJCC/UICC TNM 8th edition compared with 7th edition has been confirmed in 
several retrospective series (Ito, Miyauchi et al. 2018), (Kim, Kim et al. 2017, 
Pontius, Oyekunle et al. 2017). We must stress, however, that the risk of thyroid 
cancer recurrence for any tumor node metastasis stage can be low, intermediate 
or high (Lamartina, Grani et al. 2017). Therefore, the tumor node metastasis 
stage, which was designed exquisitely for mortality prediction, should always be 
considered together with the risk of recurrence. 
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Table 1. AJCC/UICC TNM 7th and 8th edition 
AJCC/UICC TNM 7th and 8th edition 
7th Edition Age <45 years 8th Edition Age <55 years 
I Any T Any N M0 I Any T Any N M0 
II Any T Any N M1 II Any T Any N M1 
7th Edition Age ≥45 years 8th Edition Age ≥55 years 
I T1  N0/Nx M0 I T1/T2 N0/Nx M0 
II T2  N0/Nx M0 II T1/T2/T3a 
T3b 
N1 
Any N 
M0 
M0 
III T1/T2 
T3 
N1a 
N0/Nx/N1a 
M0 
M0 
III T4a  Any N M0 
IVa T1/T2/T
3 
T4a 
N1b 
Any N 
M0 
M0 
IVa T4b  Any N M0 
IVb T4b  Any N M0 IVb Any T Any N M1 
IVc Any T Any N M1 -- -- -- -- 
 
Risk of thyroid cancer recurrence  
As discussed before, the risk of thyroid cancer death is low. Nonetheless, thyroid 
cancer patients can experience disease persistence or recurrence. Persistent 
disease refers to a patient that is not cured by the initial treatment and is found 
with evidence of disease on imaging studies at the first disease assessment 
(usually performed at about 1 year from primary treatment). Recurrent disease 
refers to patients that were free from disease at the first disease assessment and 
that are found with evidence of disease later during follow up. The risk estimate 
of persistent and recurrent disease for DTCs vary widely between cohorts: the 
risk of persistent DTC ranges from 7% to 28% (depending on the study), and the 
risk of recurrent DTC in patients who respond well to treatment is 0.2−1.4% 
(Durante, Montesano et al. 2013, Schlumberger, Leboulleux et al. 2018) (Tuttle, 
Tala et al. 2010). This data are based mainly on retrospective analyses or small 
longitudinal studies.  The American Thyroid Association (ATA) risk stratification 
system classifies the likelihood of persistent and/or recurrent disease as low 
(<5%), intermediate (5–20%) or high (>20%) based on features documented at 
the time of diagnosis (Haugen, Alexander et al. 2016) (Table 2).  
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Table 2. American Thyroid Association risk of recurrence.   
Risk of recurrence 
class 
Definition Risk 
estimate 
Low  Papillary thyroid cancer (all the following) 
- Absence of distant metastases  
- Intrathyroidal tumor, < 4cm; absence of 
macroscopic extra thyroid extension 
- Absence of clinically evident lymph node 
metastases  
- Five or less microscopic (< 2 mm) lymph node 
metastases  
- Absence of aggressive histology 
-  Absence of vascular invasion 
- Complete macroscopic tumor resection 
- No uptake outside thyroid bed on post-
therapeutic whole-body scan if radioiodine 
ablation is performed 
Follicular thyroid cancer (all the following) 
- Well differentiated 
- Capsular invasion only or less than 4 foci of 
vascular invasion  
≤5% 
Intermediate Any of the following: 
Microscopic invasion of tumor into perithyroidal soft 
tissue 
Aggressive histology 
Papillary thyroid cancer with vascular invasion 
Presence of clinically evident lymph node metastases 
(<3 cm) or more than 5 microscopic (<2mm) lymph 
node metastases  
Multifocal papillary thyroid carcinoma with 
BRAFV600E mutation  
Uptake in the neck, outside thyroid bed, on post-
treatment whole body scan 
>5%-20% 
High Any of the following: 
Macroscopic invasion of perithyroidal 
tissue/structures 
Lymph node metastases of 3 cm or more or with 
extranodal extension 
Follicular thyroid cancer with extensive vascular 
invasion 
Incomplete tumor resection 
Distant metastases 
Serum thyroglobulin suggestive of distant metastases 
>20% 
 
Small (diameter of ≤10 mm), unifocal intrathyroidal PTCs with no aggressive 
histological variant have a very low risk of recurrence (<1%) (Durante, Attard et 
al. 2010, Haugen, Alexander et al. 2016). The presence of lymph node 
metastases and of minimal extrathyroidal extension (to perithyroidal soft tissue) 
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was considered a risk factor for recurrence, but this is now a subject of debate 
(Nixon, Ganly et al. 2011). The size of the metastatic lymph nodes (≤2 mm, >2 
mm or ≥3 cm), their number (<5 or >5), the number of lymph node metastases 
with extracapsular invasion (Leboulleux, Rubino et al. 2005) and (probably) their 
location (central versus lateral compartments) should be considered in 
recurrence estimates (Randolph, Duh et al. 2012, Barbosa, Momesso et al. 2017). 
Several reports stated little influence of minimal extrathyroidal extension on 
disease recurrence when no other risk feature (such as lymph node metastasis) 
is present (Nixon, Ganly et al. 2011, Castagna, Forleo et al. 2018). It is though 
evident that in each risk class, there is a spectrum of characteristics associated 
to lower or higher risk: this has been proposed as the continuum of risk (Figure 
1) by the 2015 ATA guidelines.   
Figure 1. The continuum of risk (Adapted from Haugen, Alexander et al 2016)  
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Treatment options for differentiated thyroid cancer 
Active surveillance 
The mainstay of thyroid cancer treatment is surgery (Lamartina, Grani et al. 
2018). As discussed before, an active surveillance approach is one of the options 
that can be taken into account for selected low risk patients (subcentimetric 
tumors, no evidence of extrathyroidal extension). Pioneering Japanese studies 
have demonstrated the safety and efficacy of this approach (Ito, Miyauchi et al. 
2010, Oda, Miyauchi et al. 2016): after 10 years of sonographic surveillance only 
the 8% of the patients experienced tumor growth and the 4% had lymph node 
metastases development. Younger age (below 40 years) was found an 
independent risk factor for disease progression (either primary tumor growth or 
lymph node metastases development)(Ito, Miyauchi et al. 2014). Patients that 
had tumor progression were submitted to surgery with favorable outcomes (Ito, 
Miyauchi et al. 2014).  
A US study included, in an active surveillance protocol, tumors up to 15 mm. Of 
the 291 patients the 2.5% experienced tumor growth after a median of two years 
and the 12% after 5 years (Tuttle, Fagin et al. 2017). This study confirmed 
younger age (under 50 years) as an independent predictor of tumor progression 
(Tuttle, Fagin et al. 2017). The percentage of tumors that displayed growth is 
slightly higher in the US study compared with the Japanese study: this may be 
due to differences in the populations studied but it may be explained also by the 
different method used to assess growth. Indeed, in the US study a more accurate 
method (i.e. tumor volume increase) was used to assess tumor growth. Other 
observational clinical trials to evaluate the “active surveillance” approach in PTCs 
of ≤10 mm are ongoing in Korea and Israel (NCT02952612, NCT02938702, and 
NCT02609685).  
 
Surgery 
Traditionally, total thyroidectomy was considered the standard of care for 
thyroid tumors. A retrospective analysis of 52,173 cases (data from the SEER 
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database), thyroid lobectomy for tumors with a maximum diameter of 1 cm or 
greater was associated with small but statistically significant increases in the 
risks for recurrence (9.8% versus 7.7%) and mortality (2.9% versus 1.6%) 
compared with total thyroidectomy (Bilimoria, Bentrem et al. 2007). A recent 
retrospective analysis of SEER data found no such difference in terms of overall 
survival after more extensive risk stratification (Adam, Pura et al. 2014). 
Nonetheless, another meta-analysis shows that the risk of recurrence after 
lobectomy was significantly higher than that after total thyroidectomy (8.3% 
versus 4.4%; p<0.01)(Macedo and Mittal 2015). Tumor recurrence in the 
contralateral lobe can occur in up to the 5% of patients treated with lobectomy 
(Matsuzu, Sugino et al. 2014) and that benign nodule relapse is experienced by 
20–50% of the patients (Antunes and Taveira-Gomes 2013, Lytrivi, Kyrilli et al. 
2016, Zatelli, Lamartina et al. 2018). Lobectomy offers several advantages over 
total thyroidectomy: surgical complications are reduced. Lobectomy eliminates 
the risk of permanent hypoparathyroidism and bilateral RLN palsy and reduces 
the rates of permanent unilateral RLN palsy (0.6% in lobectomy versus 1.3% in 
total thyroidectomy) (Rosato, Avenia et al. 2004). Moreover, a half to up to the 
80% of the patients will not develop hypothyroidism and will not need 
levothyroxine replacement therapy. The rate of hypothyroidism after lobectomy 
varies from 23.6 to 47% (Balentine, Domingo et al. 2013, Lee, Seok et al. 2015).  
Therefore, thyroid lobectomy is recommended by the ATA guidelines (Haugen, 
Alexander et al. 2016), for low-risk, intrathyroidal tumors up to 4 cm in size with 
no lesions in the contralateral lobe or other benign thyroidal conditions (e.g. 
contralateral benign nodules, diffuse autoimmune thyroid disease). 
Patients with gross tumors (> 4cm), multifocal and bilateral tumors or in the 
presence of extrathyroidal extension or metastases total thyroidectomy is 
recommended (Haugen, Alexander et al. 2016). Lymph node surgery should 
always be performed in case of lymph node metastases found before or during 
surgery and should be a compartment-oriented neck dissection (Haugen, 
Alexander et al. 2016).  
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Prophylactic central neck dissection was advocated by some authors because of 
the high frequency of subclinical lymph node metastasis in DTC (Wada, Duh et 
al. 2003). It is worth to underline that microscopic lymph node metastases that 
are not clinically evident before surgery (not identified with neck ultrasound) 
have little influence in patient outcome (Randolph, Duh et al. 2012), but on the 
other hand, central  compartment neck dissection carries an increased rate of 
surgical complications (namely hypoparathyroidism) (Lee, Oh et al. 2015, Viola, 
Materazzi et al. 2015). 
A randomized prospective study compared the outcomes of the patients 
undergoing total thyroidectomy alone or total thyroidectomy and central 
compartment neck dissection. After five years of follow up no difference in the 
outcomes was found (Viola, Materazzi et al. 2015). 
 
Radioiodine treatment 
Routine use of radioiodine ablation (RRA) therapy used to be justified by the 
need to eliminate normal residual thyroid tissue in order to facilitate serum 
thyroglobulin (Tg) and 131I whole-body scan (WBS) interpretation. In addition, 
radioiodine treatment was performed with an adjuvant purpose (i.e. destroy any 
occult nests of neoplastic cells), thereby improving long-term outcomes. In 
recent years, due to the availability of accurate diagnostic tool and a better 
definition of the actual risk of DTC patients, these indications have been 
questioned (Lamartina, Durante et al. 2015). The preferred approach now days 
is to select patients for RRA based on the risk of recurrence estimate and 
eventually on the response to treatment (see below) (Lamartina, Grani et al. 
2018). Only high risk patients have shown a benefit in terms of improved survival 
with radioiodine treatment (Jonklaas, Sarlis et al. 2006). For low and 
intermediate risk patients, that have a marginal thyroid cancer death risk as 
discussed before, no such benefit has been demonstrated. For low risk patients 
several reports have demonstrated no benefits in terms of reduced recurrence 
rates (Lamartina, Durante et al. 2015) and RRA is not recommended in these 
patients (Haugen, Alexander et al. 2016). In intermediate-risk patients, evidence 
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is more controversial, and the decision to perform RRA should be based on 
individual prognostic factors (Lamartina, Durante et al. 2015). An early disease 
assessment with neck ultrasound and serum Tg level may assist RRA decision. A 
low or undetectable serum Tg level and the absence of suspicious findings on 
neck ultrasound may support the decision to avoid RAI administration 
(Lamartina, Durante et al. 2015).  
Two randomized European trials (HiLo and ESTIMABL) have demonstrated the 
non-inferiority of low (30 mCI) versus high (100 mCi) activities of radioiodine and 
preparation with either recombinant human TSH (rhTSH) or thyroid hormone 
withdrawal for remnant ablation (Mallick, Harmer et al. 2012, Schlumberger, 
Catargi et al. 2012). Therefore, low activities and rhTSH preparation should be 
preferred for RRA. Higher activities and thyroid hormone withdrawal are 
recommended when radioiodine is administered for a therapeutic purpose (i.e. 
treatment of iodine avid metastases).    
Two randomized clinical trials in Europe are ongoing and aim to obtain reliable 
data on the indications for post-operative RAI administration. In the French 
ESTIMABL2 trial (NCT01837745), 750 patients with a T1bN0,Nx tumor will be 
randomly assigned to post-operative ablation with an activity of 30 mCi after 
rhTSH stimulation or simple follow-up. The IoN trial in the UK (NCT01398085) 
has a similar design. The primary outcomes in the two studies are disease-free 
survival rates evaluated at 3 and 5 years. 
 
Response to treatment and dynamic risk assessment  
The first disease assessment is usually performed 6–18 months after the initial 
treatment, and it should be based on serum thyroglobulin and anti-thyroglobulin 
antibody assays and imaging. The response to treatment is classified into four 
categories (Table 3). Two classes, excellent response (ER) and structural 
incomplete response (SIR) define the absence or the presence of disease 
respectively. The other two categories, indeterminate response (Ind) and 
biochemical incomplete response (BIR), are used when the patient cannot be 
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classified as free from disease for the presence of detectable serum markers of 
DTC (thyroglobulin or anti thyroglobulin antibodies) or in the presence non-
specific imaging findings. BIR is usually associated to a higher risk of 
persistent/recurrent disease compared with Ind, but results in spontaneous 
remission in most of the cases (Vaisman, Momesso et al. 2012), (Lamartina, 
Montesano et al. 2016).   
Table 3. Response to treatment  
Response Definition (2015 ATA guidelines) Risk of 
recurrence  
Excellent response No abnormal finding on imaging 
AND  
basal Tg <0.2 ng/mL OR stimulated Tg <1 
ng/mL  
AND No TgAb 
<1-4%  
Biochemical Incomplete 
Response  
No abnormal finding on imaging 
AND  
basal Tg ≥1 ng/mL OR stimulated Tg ≥10 ng/mL 
OR 
Rising TgAb over time 
20% 
Indeterminate Response Nonspecific findings on imaging 
AND / OR 
basal Tg ≥0.2 - <1 ng/mL OR stimulated Tg ≥1 - 
<10 ng/mL  
OR 
Stable or declining TgAb over time 
15-20% 
Structural Incomplete 
Response 
Abnormal findings on imaging 100% 
 
The initial risk estimate can be substantially refined by the response to treatment 
assessed during follow up (Tuttle, Tala et al. 2010) (Table 3). An ER in a low risk 
patient renders the risk of recurrence almost zero  (Durante, Attard et al. 2010, 
Schlumberger, Leboulleux et al. 2018), and reduces the risk of intermediate risk 
patients to 1–2% (Vaisman, Momesso et al. 2012). Data on high risk patients are 
controversial: some reports found an important reduction of the recurrence rate 
in long term follow up equivalent to that observed for low and intermediate risk 
patients (Verburg, Stokkel et al. 2010). Other reports however found a non-
negligible residual risk of recurrence in high risk patients with ER to treatment 
(up to 14%) (Tuttle, Tala et al. 2010).  This risk increases even further (25%)  
following treatment of a recurrence (Lamartina, Borget et al. 2017).  
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Role of the histological type  
Tumor histotype plays an important role in the risks of recurrence and DTC-
related mortality. The world health organization (WHO) endocrine tumor 
classification system published in 2017 recognizes four histological classes of 
DTC:  
- Papillary thyroid cancer,  
- Follicular thyroid cancer,  
- Hürthle cell thyroid cancer  
- Poorly differentiated thyroid cancer (WHO 2017).  
PTCs is the most common type of DTC (95% of the cases). Its metastatization 
pattern follows the lymphatic vessels. Neck lymph node metastases are frequent 
and involve the neck compartment in an ordered fashion (the central 
compartment first and then lateral compartments). Distant metastases from PTC 
are rare and seldom skip neck lymph nodes. Some histological variants (e.g. tall 
cell, columnar cell, hobnail cell, sclerosing and trabecular PTCs) are more 
aggressive than their classic counterparts. A new variant called non-invasive 
follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) 
(Nikiforov, Seethala et al. 2016) was introduced with the 2017 WHO 
classification (WHO 2017). NIFTPs has indolent behavior with extremely low 
rates of local metastases (3–5%) and anecdotical reports of distant metastases 
(0.6–1%) (Cho, Mete et al. 2017, Parente, Kluijfhout et al. 2017). Given the recent 
introduction in DTC classification, data on NIFTPs are limited and, further 
evidence is needed to define their optimal management.  
Compared with PTC, FTC — particularly the widely invasive form — carries a 
more severe prognosis (Grani, Lamartina et al. 2017). Metastatization occurs 
following the blood vessels, therefore spread to distant sites (mainly the lungs 
and the bones) occurs in up to 46% of FTC patients. On the other hand,  
metastases to neck lymph nodes are rare, occurring in only 2–8% of cases (Grani, 
Lamartina et al. 2017). The WHO recognizes 3 FTCs categories according to the 
presence and extent of vascular invasion (WHO 2017). Minimally invasive FTCs 
(limited neoplastic invasion of tumor capsule and no vascular invasion) have 
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generally a good prognosis (recurrence ≈0–5% and mortality <5%) and are 
considered low-risk tumors. FTCs with limited vascular invasion might be 
considered intermediate risk (5% recurrence and 3% mortality) (Ito, Hirokawa et 
al. 2013). Widely invasive FTCs are high risk tumors (recurrence ≈30–55% and 
disease-specific mortality ≈30%) (Haugen, Alexander et al. 2016).  
HCC, traditionally considered as a subtype of FTC, is now recognized by the WHO 
as a separate entity (WHO 2017). It spreads frequently to distant sites as widely 
invasive FTC but also to neck lymph nodes in up to the 30% of the patients and 
should be considered a high-risk DTC. HCC molecular profile is different from 
that of other DTCs (Ganly, Ricarte Filho et al. 2013).  
PDTC is another high risk thyroid cancer. The diagnosis is based on precise 
histopathological criteria: the Turin criteria (Volante, Landolfi et al. 2004). These 
tumors have a poor prognosis and the 10-year survival is only 46% (Haugen, 
Alexander et al. 2016). 
 
Molecular profile  
Molecular profiling of the tumor provides prognostic and therapeutic 
information and helps to identify high-risk tumors. The Cancer Genome Atlas 
initiative has identified the 97% of the driver mutations of PTCs (Cancer Genome 
Atlas Research Network 2014). In most cases these driver mutations are 
mutually exclusive (Cancer Genome Atlas Research Network 2014). Two 
subgroups can be identified based on the genetic phenotype of PTCs: RAS-like 
tumors and BRAF-like tumors. BRAF-like tumors are less differentiated and has a 
more aggressive behavior (Elisei, Viola et al. 2012, Xing, Alzahrani et al. 2013, 
Tallini, de Biase et al. 2015, Xing, Alzahrani et al. 2015, Huang, Qu et al. 2017). 
BRAFV600E is the most common driver mutation, present in 40–60% of PTCs, 
namely in classical PTCs and the tall cell PTCs (Cancer Genome Atlas Research 
Network 2014). This mutation is associated with several pathological features 
(such as multifocality, extrathyroidal extension and lymph node metastases) 
and, in some series, with an increased risk of persistent or recurrent disease, and 
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in older patients (>45 years), this mutation has been associated with an 
increased risk of mortality (Shen, Zhu et al. 2018). Given the heterogeneity of 
the phenotype associated with the presence of the BRAFV600E mutation, 
confirmation of its presence should be considered together with the other risk 
features, and this evaluation is not routinely recommended for risk stratification. 
Profiling microRNAs seems a promising tool for identifying high-risk BRAF-like 
PTC (Rosignolo, Memeo et al. 2017). The BRAFV600E mutation can impair iodine 
metabolism (Durante, Puxeddu et al. 2007, Rosignolo, Maggisano et al. 2015), 
possibly reducing the effectiveness of radioiodine. RAS mutations occur in 10–
30% of PTCs, notably in the follicular variant and in NIFTP (Nikiforov, Seethala et 
al. 2016) (Cancer Genome Atlas Research Network 2014).  
Gene fusions were found in 15% of PTCs, with the RET–PTC translocation being 
the most frequent (6%) (Cancer Genome Atlas Research Network 2014). Several 
other gene fusions have been identified (NRTK1, NRTK3, BRAF, ALK, FGFR2, 
THADA, MET, LTK and ROS) (Cancer Genome Atlas Research Network 2014). 
Gene fusions are more common in children than in adults and occur frequently 
in radiation-induced PTCs. The coexistence of BRAFV600E and TERT promoter 
mutations has been associated with poor clinical outcomes in terms of both 
persistence and recurrence of the disease as well as survival (Xing, Liu et al. 
2014). The majority of these oncogenic gene fusions can be targeted with 
specific drugs. In FTC, RAS mutations are found in 40% of tumors, the most 
common being the codon 61 N-RAS mutation (Fukahori, Yoshida et al. 2012, 
Jang, Song et al. 2014). RAS mutations are also found in 20% of follicular 
adenomas. PAX8 and PPARG are observed in both follicular adenomas (14%) and 
FTCs (10–60%) (Lacroix, Lazar et al. 2005). PTEN somatic mutations are observed 
in 10% of FTCs. Cowden syndrome (an inheritable autosomal dominant disorder) 
is driven by a PTEN germline mutation and is associated with an increased risk of 
FTC. Other genetic abnormalities found in FTCs are PI3KCA-activating mutations 
(10%)(Liu, Hou et al. 2008). Finally, TERT promoter mutations have been 
observed in FTC and, as is the case with the mutations found in PTC, were 
associated with a more aggressive phenotype (Liu, Wang et al. 2014). In HCC, 
two molecular pathways (PI3K–AKT– mTOR and WNT–CTNNB1) are typically 
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activated (Ganly, Ricarte Filho et al. 2013). In PDTC, several mutations were 
found (BRAF, RAS, EIF1AX, TP53 and TERT promoter), the most frequent being 
the RAS mutation (Volante, Rapa et al. 2009). The accumulation of genetic 
abnormalities in a given tumor might represent the pathogenetic mechanism of 
transition from well-differentiated tumor towards PDTC (Landa, Ibrahimpasic et 
al. 2016, Ibrahimpasic, Xu et al. 2017). 
 
Tools used for follow-up  
Serum thyroglobulin  
The serum level of thyroglobulin is a highly sensitive marker for the presence of 
thyroid tissue (anywhere in the body). Thyroglobulin is produced by both normal 
and neoplastic thyrocytes. Thyroglobulin should always be measured using the 
same method (due to lack of standardization between assays) and can be 
assessed with assays with a functional sensitivity ≈1 ng/ml or with assays with a 
functional sensitivity ≈0.1–0.2 ng/ml (the so-called ultrasensitive assays). The 
sensitivity of serum thyroglobulin can be improved with TSH increase that can 
be obtained with levothyroxine withdrawal (that renders the patient 
hypothyroid) or with injections of rhTSH (Pacini, Molinaro et al. 2001). The 
negative predictive value of undetectable TSH-stimulated thyroglobulin level is 
close to 100%. Therefore, if the initial assay reveals undetectable levels, further 
monitoring of stimulated thyroglobulin offers no benefit (Castagna, Brilli et al. 
2008). Ultrasensitive thyroglobulin assays seem to remove the need for routine 
TSH-stimulated thyroglobulin determinations (Kloos and Mazzaferri 2005, 
Castagna, Brilli et al. 2008). TSH stimulation produces a fivefold to tenfold 
increase over basal values in serum levels of thyroglobulin, and, using a sensitive 
assay, TSH-stimulated serum levels of thyroglobulin can be predicted with the 
basal serum thyroglobulin determination(Spencer, Fatemi et al. 2010, Brassard, 
Borget et al. 2011). The cut-off, using the best accuracy for basal sensitive 
thyroglobulin, was reported as 0.2 ng/ml (Schlumberger, Hitzel et al. 2007, 
Malandrino, Latina et al. 2011).  
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Patients treated with simple thyroid lobectomy or total thyroidectomy not 
followed by RRA have some amounts of residual thyroid tissue. In these patients 
a single detectable thyroglobulin value is not a reliable indicator for the presence 
of residual thyroid tumor (Haugen, Alexander et al. 2016). Some reports have 
demonstrated that the trend of thyroglobulin over time is a reliable predictor of 
the disease status of the patients (Durante, Montesano et al. 2012, Angell, 
Spencer et al. 2014): a stable or declining trend is consistent with disease 
remission while a rising trend is highly suspicious for disease relapse.    
 
Anti-thyroglobulin antibodies 
Thyroglobulin antibodies should always be measured at each thyroglobulin 
assessment because they can interfere with thyroglobulin assays leading false 
negative or more rarely false positive results (Haugen, Alexander et al. 2016). 
Mass spectrometry has demonstrated to overcome this problem in experimental 
settings (Netzel, Grebe et al. 2015, Netzel, Grant et al. 2016), but this approach 
seems to be less effective in clinical practice than it is in the research setting 
(Azmat, Porter et al. 2017). Thyroglobulin antibody titres over time (using the 
same assay) can provide surrogate information on disease recurrence, and 
declining titres are usually associated with remission (Durante, Tognini et al. 
2014, Rosario, Carvalho et al. 2016, Matrone, Latrofa et al. 2018). 
 
Neck ultrasonography and cytology  
Most recurrences of PTCs are localized in the neck. The ultrasonographic 
characteristics use for the identification of metastatic neck lymph nodes and 
thyroid bed relapses has variable sensitivity and specificity (Leboulleux, Girard 
et al. 2007, Shin, Han et al. 2007, Leenhardt, Erdogan et al. 2013, Lamartina, 
Deandreis et al. 2016). Of note, up to 18% of histologically benign lymph nodes 
display suspicious features on ultrasonography (Leenhardt, Erdogan et al. 2013). 
The European Thyroid Association guidelines identify groups of characteristics 
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that can be used to distinguish indeterminate from suspicious findings 
(Leenhardt, Erdogan et al. 2013).   
Roughly two-thirds of neck lymph nodes classified as indeterminate will 
spontaneously disappear (Lamartina, Grani et al. 2016), and watchful waiting is 
thus appropriate for small indeterminate nodes. Overall, only a small proportion 
of lesions will grow over time, and complications due to size increases have not 
been reported to date (Rondeau, Fish et al. 2011, Robenshtok, Fish et al. 2012) 
(Lamartina, Grani et al. 2016). Recurrences in the surgical bed usually appear 
hypoechoic — i.e. tissue darker than normal thyroid tissue — with 
microcalcifications, cystic component, irregular margins and increased 
vascularity, but this appearance can be found also in scar tissue or granulomas 
leading to  false-positive ultrasonographic findings in 26–35% of the cases (Shin, 
Han et al. 2007, Kamaya, Gross et al. 2011, Leenhardt, Erdogan et al. 2013). Fine-
needle aspiration cytology of thyroid bed nodules or neck lymph nodes can be 
employed in those cases that will be referred to surgery in case of findings 
consistent with malignancy (i.e. lesions of at least 8 mm in small diameter or 
lesions that represent a potential threat for their location) (Choudhary, 
Wartofsky et al. 2015, Haugen, Alexander et al. 2016). The sensitivity of fine-
needle aspiration of lymph nodes can be increased by means of thyroglobulin 
measurement in the washout fluid and molecular testing (Arturi, Russo et al. 
1997, Grani and Fumarola 2014). Smaller lesions and lesions not located in 
threatening sites can be managed with active surveillance (Rondeau, Fish et al. 
2011, Robenshtok, Fish et al. 2012) (Lamartina, Grani et al. 2016). The 
documented increased use of neck ultrasonography in patients with DTC 
observed between 1998 and 2011 was associated with increased rates of 
treatment (surgery or radioiodine) but not with improved survival (Banerjee, 
Wiebel et al. 2016). 
 
Whole-body radioactive iodine scan  
Before the advent of neck ultrasonography, diagnostic whole-body scan with 
radioactive iodine was the cornerstone of DTC follow-up. Given the superior 
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diagnostic accuracy of other imaging techniques, in patients with a post-
therapeutic whole-body scan that is considered normal (defined as the absence 
of radioactive iodine uptake outside of the thyroid bed), there is no longer any 
need for diagnostic whole-body scans (Cailleux, Baudin et al. 2000, Pacini, 
Capezzone et al. 2002). Several retrospective studies have shown that diagnostic 
whole-body scans do not improve the detection of neck recurrences during 
follow-up over the detection that can be achieved with serum thyroglobulin 
assays and neck ultrasonography (Pacini, Agate et al. 2001, Torlontano, Crocetti 
et al. 2006, Gonzalez Carvalho, Gorlich et al. 2017). 
 
Cross-sectional imaging  
Given the rarity of distant metastases in patients with DTC, second-line tools, 
such as cross-sectional imaging (CT scan or MRI) and 18F-fluorodeoxyglucose 
(FDG)– PET, are not routinely used in patients with DTC but can provide valuable 
information in certain cases. Cross-sectional imaging is the method of choice for 
identifying distant metastases owing to its high anatomical definition. The 
RECIST criteria can be applied to CT and MRI images to identify morphological 
disease progression or to evaluate responses to treatment. A CT scan without 
contrast enhancement is an effective tool for lung imaging, and CT with contrast 
medium can be used for the assessment of lesions in the neck and mediastinum 
(Lamartina, Deandreis et al. 2016). MRI provides complementary results for neck 
imaging and is the best tool for detecting respiratory and digestive tract spread. 
MRI is also the method of choice for imaging bone lesions88. 18F-FDG–PET–CT 
is effective to screen lesions, including in bones, in a single  procedure and 
provides prognostic information (Leboulleux, Schroeder et al. 2007). 
 
Novel biomarkers for thyroid cancer: role of miRNA 
As discussed in the previous sections, thyroglobulin, the serum biomarker used 
together with imaging to assess disease status of DTC patients, has several 
limitations (notably in the presence of residual thyroid tissue or in the presence 
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of anti-thyroglobulin antibodies that can interfere with thyroglobulin assays). 
The research for alternative biomarkers is therefore an active field of research. 
miRNAs are endogenous, noncoding RNAs. Their length ranges from 19 to 25 
nucleotides. miRNA have an important role in the posttranscriptional regulation 
of gene expression (Bartel 2009, Shukla, Singh et al. 2011). miRNAs can reduce 
the stability of a target gene transcript or inhibit its translation resulting in the 
downmodulation of the target gene expression (Bartel 2009, Shukla, Singh et al. 
2011). This regulatory role on gene expression is important for several 
physiologic process, including those involved in embryogenesis and postnatal 
development. miRNA dysregulation is associated to several pathological 
conditions, including malignant tumors (Lagos-Quintana, Rauhut et al. 2001, 
Iorio and Croce 2017, Oliveto, Mancino et al. 2017). Over 2000 annotated human 
miRNAs are reported in the miRBase database (Kozomara and Griffiths-Jones 
2014). Thyroid tumors (like other cancers) display alterations involving miRNA 
biogenesis at different levels. Malignant thyroid tissues and cell lines have 
downregulated transcription of DICER as compared with normal thyroid tissues 
and benign thyroid neoplasms (Penha, Sepe et al. 2017). This alteration was 
associated with “aggressive” tumor features (e.g. extrathyroidal extension, 
lymph node and distant metastases) and recurrence (Erler, Keutgen et al. 2014). 
DICER downregulation was also associated with the presence of the BRAFV600E 
mutation (Erler, Keutgen et al. 2014). Specific patterns of miRNA expression have 
been described in thyroid carcinomas (Nikiforova, Tseng et al. 2008, Dettmer, 
Vogetseder et al. 2013), and several miRNAs were found overexpressed or 
downregulated in major types of thyroid tumors (Nikiforova, Chiosea et al. 2009, 
Fuziwara and Kimura 2017). The overexpression of miRNA-146b, miRNA-221, 
miRNA-222, and miRNA-181b in PTCs as compared with expression levels in 
normal thyroid tissues was described in several reports. This upregulation is 
found associated with a more aggressive behavior of the tumors (Chou, Chen et 
al. 2010, Zhou, Liu et al. 2012, Wang, Zhang et al. 2013, Rosignolo, Memeo et al. 
2017) [33–37]. miRNA-146b, miRNA-221, and miRNA-222, are also upregulated 
in FTC, HCC, and anaplastic thyroid carcinoma (Fuziwara and Kimura 2014, 
Wojtas, Ferraz et al. 2014, Petric, Gazic et al. 2016). In contrast, miRNA-197 and 
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miRNA-346 are upregulated specifically in FTC (Weber, Teresi et al. 2006). The 
miRNA-17-92 cluster is highly expressed in ATC (Fuziwara and Kimura 2014)[39].  
Some of miRNA molecular targets are genes with a regulatory role in cell 
proliferation, migration invasion and survival. Some examples are: proto-
oncogene receptor tyrosine kinase (KIT) (target of miRNA-146b, miRNA-221, 
miRNA-222), C-X-C motif chemokine ligand 12 (CXCL12) (target of miRNA-137), 
connective tissue growth factor (CTGF) (target of miRNA-199a-5p), NF-kB (target 
of miRNA-146a) (He, Jazdzewski et al. 2005, Pacifico, Crescenzi et al. 2010, Dong, 
Jin et al. 2016, Sun, Han et al. 2016). 
 
miRNA Detection in Biological Samples  
Several pathologic conditions including several malignant tumors are associated 
with significant changes in the miRNA profile (Di Leva, Garofalo et al. 2014). 
miRNAs can be found in cell lines, fresh-frozen and formalin-fixed tissues, fine 
needle aspiration biopsy samples, blood plasma and serum, and urine and ill all 
this specimens demonstrate a good stability (Makarova, Shkurnikov et al. 2016). 
Therefore, several approaches have been developed to isolate miRNA and study 
their expression, with the aim to identify profiles or single miRNAs associated 
with specific pathological condition.  
The first step of the process is the isolation of total RNA. The extraction protocols 
used are designed to enrich the fraction containing miRNAs and other small RNA. 
Chemical miRNA extraction methods and column-based miRNA extraction 
methods are the most used. Chemical methods are suitable for all biological 
specimens and provide high amounts of RNA but may be prone to chemicals 
contamination. Column based methods provide more pure and high quality RNA 
but specific kit for each kind of biological tissue studied is needed (Celano, 
Rosignolo et al. 2017). The isolated miRNA is then quantified and subjected to 
quality assessment. The quantity of the RNA obtained depends on the specimen, 
while the quality depends on the extraction method adopted. The methods 
currently used to analyze miRNA expression are: microarrays, quantitative 
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reverse-transcription PCR (qRT-PCR), high-throughput sequencing (RNA-seq), 
and digital PCR (dPCR). Microarray analysis allows rapid parallel analysis of large 
numbers of miRNAs. The miRNAs in a biological sample are labeled using 
fluorescent, chemical, or enzymatic techniques and then hybridized to DNA-
based probes on the array. Microarray-based profiling cost is relatively 
inexpensive, but its sensitivity and specificity are lower compared with other 
miRNA profiling methods. QRT-PCR entails reverse transcription of miRNA to 
cDNA, followed by real-time monitoring of the accumulation of polymerase 
reaction products. Platforms with preplated PCR primers distributed across 
microfluidic cards containing nanoliter-scale wells allow qRT-PCR detection of 
hundreds of miRNAs. This approach is more specific and sensitive than 
microarray profiling. An internal control is needed for relative quantification of 
the expression; for absolute quantification, a standard curve can be employed. 
RNA-seq provides quantification data as well as sequence data and can therefore 
be used to identify novel miRNAs or sequence variations. A cDNA library of small 
RNAs is prepared from the samples of interest. The second step adaptor ligation 
and immobilization of the cDNA on a support that can be either solid (for solid-
phase PCR) or bead-based (for emulsion PCR). Massive parallel sequencing of 
millions of cDNA molecules from the library is then performed allowing 
simultaneous analysis of the expression patterns of a huge number of targets. 
This technique of miRNA profiling is the most informative but also the most 
expensive. Digital PCR allows quantitative analysis of miRNA expression. It is the 
most sensitive technique, internal controls are not needed for quantification, 
and is the only technique capable of direct miRNA absolute copy number 
quantification. A cDNA sample is partitioned into multiple parallel PCR reactions 
performed with nanofluidics partitioning or emulsion chemistry. Digital PCR is 
superior to previously described methods in terms of sensitivity and precision, 
and it is the most suitable technique to study miRNA expression in plasma or 
serum samples, where stable endogenous controls are laking (Moldovan, Batte 
et al. 2014, Hunt, Broyles et al. 2015, Celano, Rosignolo et al. 2017). 
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miRNAs as Diagnostic Markers in Thyroid Cancer  
Molecular testing is a useful tool for the identification of malignant or benign 
nodules when fine needle cytology yields indeterminate findings (Durante, Grani 
et al. 2018).  miRNAs are promising molecular marker in this setting (Paskas, 
Jankovic et al. 2015, Boufraqech, Klubo-Gwiezdzinska et al. 2016, Stokowy, 
Wojtas et al. 2016, Wei, Shen et al. 2016).  
Another field of active research are the so called “liquid biopsies”. The liquid 
biopsies aim to identify molecules in peripheric blood as markers for tumor 
diagnosis and potentially provide a picture of both primary and metastatic tumor 
lesions (Ilie and Hofman 2016, Larrea, Sole et al. 2016). Some reports on the role 
of miRNA in PTC show variable results. Differences in the populations studied 
and in methodology (i.e., sample type, storage conditions, and/or sample 
processing, RNA extraction protocol, quantification methods) probably 
contribute to this variability. The miRNA studied as circulating markers in DTCs 
are reported in Table 4. 
Table 4. Circulating miRNA in PTC and FTC (adapted form Celano et al. 2017) 
Histotype Sample analyzed miRNA Regulation 
PTC Serum 
let-7e, 151-5p, 222, hsa-let7b-5p, hsa-
miR-10a-5p, hsa-miR-93-5p, hsa-miR-
191, 24-3p, 28-3p, 103a-3p, 146a-5p, 
146b-5p, 191-5p, 221-3p, 222-3p 
Up 
 Serum 95, 21 Down 
 Plasma 
146b, 222, 190, let-7i, 25-3p, 140-3p, 
451a, 146b, 155, 31-5p, 126-3p, 145-
5p, 181a 
Up 
 Plasma 
hsa-miR-146a-5p, hsa-miR-150-5p, 
hsa-miR-199b-3p, has-miR-342-3p 
Down 
 
Plasma-derived 
exosomes 
31-5p, 126-3p, 145-5p, 181a Up 
FTC 
Plasma-derived 
exosomes 
21 Up 
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Circulating levels of miRNA-146b5p, miRNA-221-3p, and miRNA-222-3p can 
discriminate PTC patients form healthy controls (Yu, Liu et al. 2012, Lee, Zhao et 
al. 2013), while miRNA-222 and miRNA-146b levels discriminate between PTCs 
and benign nodules (Yu, Liu et al. 2012, Lee, Lim et al. 2015). Higher levels 
miRNA-21 are found in FTC patients compared with patients with benign nodules 
or PTC (Samsonov, Burdakov et al. 2016) (Samsonov, Burdakov et al. 2016). A 
higher expression of miRNA-181a was found in PTC patients compared with FTC 
patients (Samsonov, Burdakov et al. 2016). Circulating levels of miRNA-146a-5p, 
miRNA-146b-5p, miRNA-221-3p, and miRNA-222-3p decline after thyroid 
surgery in PTC patients (Yu, Liu et al. 2012, Lee, Zhao et al. 2013) (Yoruker, 
Terzioglu et al. 2016).  
 
 miRNAs as Prognostic Markers in Thyroid Cancer 
Some evidence is suggesting that prognostic information can be provided by 
miRNA profiling in PTCs. The expression levels of some miRNAs in thyroid tumor 
tissues are associated with: tumor size (miRNA-221, miRNA-222, miRNA-135b, 
miRNA-181b, miRNA-146a, and miRNA-146b), multifocality (miRNA-146a, and 
miRNA-146b), capsular or vascular invasion (miRNA-146b, miRNA-221, and 
miRNA-222), extrathyroidal extension (miRNA-221, miRNA-222, miRNA-146a, 
miRNA146b, miRNA-199b-5p, and miRNA-135b), and both lymph node (miRNA-
221, miRNA-222, miRNA-21- 3p, miRNA-146a, miRNA-146b, and miRNA-199b-
5p), distant metastases (miRNA-146b, miRNA-221, and miRNA-222), and 
advanced TNM stage (miRNA-146a, miRNA146b, miRNA-221, and miRNA-222). 
(Huang, Liao et al. 2013, Sun, Yu et al. 2013, Wang, Zhang et al. 2013, Acibucu, 
Dokmetas et al. 2014, Peng, Li et al. 2014, Sun, Fang et al. 2015). Higher risk of 
recurrence class, defined according to the ATA guidelines, has been positively 
associated with higher expression of miRNA-146b-5p, miRNA-146b-3p, miRNA-
21-5p, miRNA-221, miRNA222-3p, miRNA-31-5p, miRNA-199a-3p/miRNA-199b-
3p, miRNA-125b, and miRNA-203 and lower expression levels of miRNA-1179, 
miRNA-7-2-3p, miRNA-204-5p, miRNA138, miRNA-30a, and let-7c (Geraldo and 
Kimura 2015, Rosignolo, Memeo et al. 2017). One report studied the prognostic 
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role of miRNAs in follicular thyroid cancer. The expression in tumor tissue of 
miRNA-10b was found an independent predictor of worse prognosis in FTCs as it 
was associated with the presence of distant metastases in minimally invasive 
follicular thyroid cancer and to the aggressive widely invasive histotype 
(Jikuzono, Kawamoto et al. 2013). Finally, serum levels of miRNA-221-3p and 
miRNA-146a-5p appear to predict disease response to treatment in PTC: their 
levels were found increased in patients with structural evidence of disease 
(Rosignolo, Sponziello et al. 2017).  
 
The Italian Thyroid Cancer Repository 
Italian Thyroid Cancer Observatory (ITCO) foundation involves physicians, 
scientists, and patients with interests in thyroid cancer 
(www.itcofoundation.org).  The principal aims of the foundation are: a) promote 
thyroid cancer basic, clinical and translational research; b) create a 
multidisciplinary network of experts willing to share knowledge and tools for 
thyroid cancer patient care; and c) to provide scientific support for healthcare 
policy makers (Lamartina, Durante et al. 2017). The ITCO network currently 
includes 46 centers involved in the care of thyroid cancer patients, spread 
throughout the Italian territory. They include tertiary referral centers operating 
at the national level, teaching-hospitals and academic institutions as well as local 
or regional hospital-based units. 
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AIM OF THE STUDY 
The aims of this study were to: 
- describe the response to treatment evaluated after 1 and 3 years from 
surgery;  
- validate the 2015 ATA risk of recurrence classification;  
- study the role of miRNA profiles in the assessment of the response to 
treatment of DTCs.  
 
MATERIALS AND METHODS 
Study population 
A web-based thyroid cancer database was set up in the setting of the ITCO 
network. The Web-based database started the enrollment of patients with 
newly diagnosed and histologically confirmed thyroid cancer in 2013 at the 
Thyroid Cancer Center of the University of Rome Sapienza (the ITCO network’s 
coordinating center). It was then expanded to include data from centers that 
joined the ITCO. It now includes prospectively collected data on 6000 Italian 
patients with histologically confirmed diagnoses of thyroid cancer of either 
follicular of C-cell origin. Cases are considered eligible if contact with the 
reporting center began within 12 months from primary treatment. Each case 
record includes information on patient demographics and biometrics, 
circumstances of the diagnosis, tumor pathology, surgical and radioactive iodine 
treatments, and the results of periodic follow-up examinations. Sensitive data 
are encrypted, and the database is managed in an anonymous fashion.  
For the purpose of this study DTC patients were included in the analysis. Cases 
with medullary and anaplastic thyroid cancer were excluded as well as those 
with tumors of uncertain malignancy potential. Cases with incomplete 
information on the initial treatment, tumor pathology or 1-year follow up 
assessment were excluded.  
For each case, the following information was recorded: 
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A) Initial treatment: Thyroid surgery procedure (total thyroidectomy, thyroid 
lobectomy, or lobectomy followed by completion thyroidectomy); cervical 
lymph node dissection (none, central compartment dissection, lateral 
compartment dissection, central and lateral compartment dissection). For 
patients who had undergone total thyroidectomy (in one or two procedures), 
the use of RRA (performed or omitted) was also recorded. The date of last 
surgical procedure was considered as the date of primary treatment. 
In patients submitted to RRA the administered activity, the method of 
preparation (thyroid hormone withdrawal or recombinant human TSH 
stimulation) and the results of iodine post-therapeutic whole-body scan (RxWBS) 
were recorded. 
B) The risk of recurrence category was assigned in accordance with the 2015 ATA 
guidelines as follow: 
- Low risk: intrathyroidal tumors of any size, uni- or multifocal, without lymph 
node or distant metastases, no aggressive histotype, no foci of vascular invasion 
- Intermediate risk: either presence of lymph node metastases (except for bulky 
metastases of >30 mm), minimal extrathyroidal extension, aggressive histotype 
(i.e. solid, insular, tall-cell, columnar-cell, hobnail-cell, sclerosing, poorly 
differentiated, trabecular), or foci of vascular invasion  
- High risk: either presence of gross extrathyroidal extension, bulky lymph node 
metastases of >30 mm, grossly incomplete tumor resection (R2) or distant 
metastases. 
When the information on the size of lymph node metastasis was not available 
and no other high-risk features were present patients where included in the 
intermediate risk category.    
FTCs and HCCs were also analyzed separately from other DTCs. FTCs were 
classified as widely invasive (presence of extensive vascular or capsular invasion) 
or minimally invasive (absence of such extensive invasion). 
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The response to treatment was evaluated at about 1 year after surgery (range 6-
18 months) and at about 3 years from surgery (range 30 – 42 months) and was 
categorized according to 2015 ATA guidelines as:  
- ER: no evidence of disease on imaging, undetectable serum thyroglobulin 
(Tg) (≤0.2 ng/mL on levothyroixine treatment or <1 after TSH stimulation), 
absence of anti-thyroglobulin antibodies (TgAbs)  
- BIR: no evidence of disease on imaging, detectable serum Tg ≥1 ng/mL on 
levothyroxine treatment or ≥10 ng/mL after TSH stimulation or TgAbs 
positivization 
- SIR: evidence of disease on imaging  
- Ind: aspecific findings on imaging or low detectable serum Tg >0.2 and <1 
ng/mL on levothyroxine treatment or ≥1 and <10 ng/mL after TSH 
stimulation or presence of TgAbs.  
The response to treatment was also categorized in two classes as absence of SIR 
(absence of disease on imaging, i.e. ER+BIR+Ind) and SIR (evidence of disease on 
imaging).   
Presence of SIR after 1 year from primary treatment was considered synonym of 
persistent disease. Disease relapse was defined as SIR found at the 3 years 
evaluation in a patient classified ER at 1 year.  At the 3 years evaluation a 
composite outcome of persistent and recurrent diseases was also evaluated.  
  
Statistical analysis 
In descriptive analysis, continuous variables were expressed as medians with 
interquartile ranges (IQR), and nominal variables as numbers and percentages. 
Differences between categoric variables were calculated with the chi square 
test; differences between continuous variables were assessed with the Mann–
Whitney test. All statistical analyses were performed with SAS software (SAS 
Institute, Inc.). 
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Methods: miRNA profile analysis  
 
Patients and sample collection 
Consecutive PTC patients followed at the thyroid cancer unit of the university of 
Rome Sapienza and referred to total thyroidectomy that provided consent to 
participate to the study were enrolled. Serum samples were collected before 
surgery (just after anesthesia induction) and 30 days after surgery. For HCs a 
single sample was obtained at the moment of study enrollment.  
Age- and sex-matched controls and healthy controls (HC) were enrolled in the 
study. Controls were patients who underwent total thyroidectomy for nodules 
with indeterminate cytology (Bethesda Class IV) that were subsequently 
diagnosed as benign on the basis of surgical histology. HC were patients seen in 
the hospital’s outpatient clinics for health problems unrelated to the thyroid. All 
the HCs had no evidence of thyroid-disease based on the results of a screening 
examination performed by the study team (complete patient and family 
histories, neck ultrasound findings, and results of thyroid hormone and thyroid 
antibody assays).  
Blood samples were collected and centrifuged at 3000 rpm for 10 minutes. The 
serum obtained was stored at –80°C. 
 
RNA Isolation from Serum Samples 
Total RNA (including small RNAs) was extracted from 200 mL of serum using the 
miRNeasy Serum/Plasma kit and cel-miR-39 as the spiked-in control (Qiagen, 
Hilden, Germany) following the manufacturer’s instructions. To perform miRNA 
profiling without the preamplification step, we used a multiple extraction 
method: isolation of total RNA was made from up to 5 200-mL aliquots of each 
serum sample. This solution yeld over 1000 ng of total RNA from each sample. 
NanoDrop Spectrophotometer (Thermo Fisher Scientific, Inc., Waltham, MA) 
was used to verify the quality and quantity of RNA samples. 
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Retrotranscription and real time PCR  
The reaction of retrotranscription was prepared in a volume of 15 µl, containing 
5 µl of total RNA (5 ng), 3 µl of RT Primers (5X), 0.15 µl of dNTPs with dTTP (100 
mM), 1 µl of MultiScribe Reverse Transcriptase (50 U/µL), 1.5 µl of RT Buffer 
(10X), 0.19 µl of RNase Inhibitor (20 U/µL) and 4.16 µl of Nuclease-free H2O.  
For the first cDNA strand synsthesis the retrotranscription mix was incubated at 
16°C for 30 min, at 42°C for 30 min, at 85°C for 5 min and finally stored at 4°C.  
Then, 1.33 µl of cDNA was amplified by Real-Time PCR using 10 µl of TaqMan 
Universal PCR Master Mix, No AmpErase UNG (2X), 1µl of microRNA TaqMan 
Assay and 7.67 µl of nuclease-free H2O in a final volume of 20 µl. The 
amplification reaction was undertaken with Real-Time PCR 7900HT (Thermo 
Fisher Scientific) using the following schedule: 10 min at 95°C, followed by 40 
cycles of 15s at 95°C and 1 min at 60°C.  
 
Screening cohort 
A first analysis of miR profiles was performed in the samples obtained from a 
cohort of PTC patients.  In this cohort (screening cohort) miRNA profiling was 
performed with TaqMan Array Human MicroRNA A+B Cards, version 3.0 
(Thermo Fisher Scientific, Inc.), constituted by a set of two 384-well microfluidic 
cards for the quantitative expression of 754 miRNAs. Reverse transcription and 
real-time polymerase chain reaction reactions were performed without a 
preamplification step (as for manufacturer’s instructions) which requires 
preamplification only if the total amount of RNA is less than 350 ng. Expression 
Suite software, version 1.0.3 (Thermo Fisher Scientific, Inc.), was used to 
calculate cycle threshold (Ct) values (cutoff: 35) and for the analysis of the data. 
U6 demonstrated the lowest between-sample variance and was used as the 
endogenous control. The relative miRNA expression levels were calculated using 
the comparative 2-∆∆Ct method. Differences in preoperative and postoperative 
miRNA expression levels were assumed significant if the fold change was >2 or 
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<0.5 and p < 0.05. Based on these results a subset of miRNAs was selected for 
validation analysis.  
 
Validation cohort 
The validation cohort included PTC patients and age- and sex-matched controls. 
The miRNAs analyzed were selected on the basis of the results obtained from 
the analysis of the screening cohort and data in the literature. Expression levels 
were quantified in duplicate using specific TaqMan MicroRNA Assays (Thermo 
Fisher Scientific, Inc.) as indicated by manufacturer’s instructions. The 
abundance of circulating miRNA was quantified with standard curves 
constructed with synthetic RNA oligonucleotides corresponding to mature 
miRNA sequences (miScript miRNA mimics, Qiagen, miRBase Release, version 
21). The mimics were reverse transcribed with specific primers (5x) together 
with the cDNA of the samples diluted serially 10-fold and then used to generate 
standard curves for each miRNA TaqMan assay. The absolute number of miRNA 
copies was determined from each sample Ct using the following equation: y=kx+ 
m, where y is the Ct value, k is the slope, x is the logarithm of the number of 
miRNA copies, and m is the y intercept. A normalization factor (NF) was 
calculated for each sample using the following formula: NF = 1/[2^(median spike 
in Ct value) – (spike in average Ct value of the given sample)]. A normalized copy 
number value was obtained for each sample by multiplying the number of copies 
of the given miRNA by the NF. Assuming that in each PCR reaction 0.4 ng of cDNS 
were added, the normalized copy number was converted to normalized copies 
of cDNA per nanogram and then to normalized copies of miRNA per milliliter of 
serum (considering the total amount of RNA isolated from 200 mL of serum). 
 
Statistical Analysis 
The Mann-Whitney test was used to assess differences in miRNA expression 
levels between preoperative and postoperative serum samples. The Kruskal 
Wallis test followed by Dunn’s multiple comparisons test was used when more 
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than 2 groups were compared. P values < 0.05 were considered statistically 
significant. All these analyses were performed with GraphPad Prism software, 
version 5.0 (GraphPad Software Inc., San Diego,CA). Receiver-operating 
characteristic (ROC) curves and areas under the ROC curve were analyzed with 
the p-ROC package in R software, version 3.1.1, using the Youden Index and the 
DeLong method. 
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RESULTS 
Study population with at least 1 year of follow up  
After the exclusion of patients that didn’t reach 1 year of follow up and those 
with incomplete data on treatment, pathology or for treatment response 
classification (i.e. serum markers and imaging), 2730 subjects were enrolled in 
the study. 
The characteristics of these subjects are summarized on Table 5.  
Table 5. Characteristics of the study population 
 
No. patients 2730 
Gender - N (%) 
Female 
Male  
 
 
2019 (74%) 
711 (26%) 
Age - median (range) 49 (10 - 89) 
Histology - N (%) 
-  Papillary 
-  Follicular  
-  Hürthle  
-  Other (mixed tumors) 
 
2532 (92.7%) 
138 (5%) 
49 (2%) 
11 (0.3%) 
Tumor size – median (range) 12 (2 - 162) 
Risk of recurrence ATA - N (%)  
- Low 
- Intermediate 
- High 
 
1386 (50.8%) 
1168 (42.8%) 
176 (6.4%) 
Surgery - N (%) 
- Total/near total thyroidectomy 
- Lobectomy+completion thyroidectomy 
- Lobectomy  
 
2619 (95.9%) 
51 (1.9%) 
60 (2.2%) 
Lymph node dissection - N (%) 
-  No 
- Central compartment 
- Central and lateral compartments 
- Lateral compartments 
 
1634 (60%) 
786 (29%) 
261 (10%) 
49 (1%) 
Radioiodine remnant ablation/treatment - N (%) 
- Performed 
- Not performed 
 
1793 (65.7%) 
937 (34.3%) 
Radioiodine preparation - N (%) 
- rhTSH 
- thyroid hormone withdrawal 
- unknown 
 
795 (44.3%) 
938 (52.3%) 
60 (3.4%) 
Radioiodine activity (mCi) - median (range)  99 (30 - 200) 
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The 74% of the cohort was female. The median age at diagnosis was 49 years 
old. The most common histotype was PTC (about 93%). Median tumor size was 
12 mm (range 2 – 162 mm). The most used surgical approach was total or neat 
total thyroidectomy (in one or two procedures) while only the 2.2% of the 
patients underwent a simple thyroid lobectomy. Lymph node dissection was 
performed in the 40% of the patients. Radioiodine remnant ablation (RRA) was 
performed in 2/3 of the cases, with a median activity of radioiodine of about 100 
mCi. Preparation to RRA was thyroid hormone withdrawal in about a half of the 
cases, 44% had recombinant human TSH stimulation (the information was 
missing in 60 subjects).   
The risk of recurrence was low in a half of the patients (50.6%), intermediate in 
the 43% and high in 6.4%.  
 
Treatment according to ATA risk 
Thyroid lobectomy was the ultimate surgical procedure in 46 (3.3%) low risk 
patients and in 14 (1.2%) intermediate risk patients. All the 6 high risk patients 
initially treated with thyroid lobectomy underwent completion thyroidectomy 
(Table 6).  
Table 6. Surgical approach according to risk of recurrence 
 
Surgical approach   
ATA risk of 
recurrence 
Bilateral 
procedure 
Lobectomy p OR [95% CI] 
Low 1340 (96.7%) 46 (3.3%) ref ref 
Intermediate 1154 (98.8%) 14 (1.2%) <0.01 
2.8285 
[1.5184 - 5.6008] 
High 176 (100%) - <0.01 
INF 
[1.5544 - INF] 
Total 2670 (97.8%) 60 (2.2%)   
Fisher exact test 
Of the 2670 patients treated with bilateral thyroid tissue removal (i.e. total/near 
total thyroidectomy or thyroid lobectomy followed by completion 
thyroidectomy) RRA was performed in 1793 (67.2%) and omitted in 877 (32.8%). 
RRA was omitted more frequently in low risk patients (722/1340 - 54%) than 
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intermediate risk patients (150/1155 – 13%) and seldom in high risk patients 
(5/176 – 2.8%). The odds ratio of receiving RRA increased with increasing risk of 
recurrence (Table 7).    
Table 7. Radioiodine remnant ablation according to risk of recurrence     
ATA risk of 
recurrence RRA Omitted RRA Performed p OR [95% CI] 
Low 722 (54%) 618 (46%) ref ref 
Intermediate 
150 (13%) 1004 (87%) 
 
<0.01 
7.8128 
[6.3609 – 9.637] 
High 
5 (2.8%) 171 (97.2%) 
 
<0.01 
39.8965 
[16.607 – 125.4165] 
Total 877 (32.8%) 1793 (67.2%)   
Fisher exact test 
Follow up tools 
All patients underwent serum thyroglobulin and anti-thyroglobulin antibodies. 
Most patients had neck ultrasound (2675 – 98%); 55 patients were evaluated 
with RAI scan (N=16), 18 FDG PET (N=30), cross sectional imaging (CT, MRI, N=9). 
  
Response to treatment evaluated at 1 year from primary surgery 
1. Whole cohort 
The response to treatment after 1 year was ER in 1675 (61.4%), BIR 63 (2.3%), 
SIR in 70 (2.6%) and Ind 922 (33.8%).  The outcome at 1 year form primary 
surgery according to ATA risk is represented in Table 8. The probability of SIR 
increased with increasing risk while the probability of ER decreased with 
increasing risk. Taking into account the outcome in two classes (presence or 
absence of SIR), the OR for SIR was significantly higher in intermediate (4.85) and 
high risk (35.21) compared with low risk patients (Table 9).  
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Table 8. Response to treatment (four classes) according to ATA risk 
 Outcome  
ATA risk of 
recurrence ER BIR SIR Ind Total 
Low 900  
(64.9%) 
42 
(3%) 
8 
(0.6%) 
436  
(31.5%) 
1386 
Intermediate 713  
(61.1%) 
19 
(1.6%) 
32 
(2.7%) 
404  
(34.6%) 
1168 
High 62 
(35.2%) 
2 
(1.1%) 
30 
(17.1%) 
82 
(46.6%) 
176 
Total 1675  
(61.3%) 
63 
(2.3%) 
70 
(2.6%) 
922 
(33.8%) 
2730 
 
Table 9. Response to treatment (two classes) according to ATA risk 
 Outcome    
 ATA risk of 
recurrence 
Absence of 
SIR 
SIR Total p 
OR  
[95%CI] 
Low 
1378 
(99.4%) 
8  
(0.6%) 
1386 ref ref 
Intermediate 
1136 
(97.3%) 
32  
(2.7%) 
1168 <0.01 
4.85 
[2.1776 - 12.23] 
High 
146 
(82.9%) 
30  
(17.1%) 
176 <0.01 
35.2163  
[15.4088 - 90.6602] 
Total 2660 (97.4%) 70 (2.6%) 2730   
Fisher exact test 
The outcome in two classes according to surgical approach in shown in Table 10. 
None of the patients treated with lobectomy alone had persistent disease after 
1 year from surgery.  
Table 10. Outcome in two classes according to surgical approach 
Surgical approach Absence of SIR SIR Total 
Total thyroidectomy 2550 (97.4%) 69 (2.6%) 2619 
Lobectomy 60 (100%) - 60 
Lobectomy+ 
completion 
thyroidectomy 
50 (98%) 1 (2%) 51 
Total 2660 (97.4%) 70 (2.6%) 2730 
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2. Papillary thyroid cancer 
The outcome evaluated at 1 year from primary surgery in PTC patients treated 
with bilateral thyroid tissue removal according to ATA risk class and RRA 
treatment is shown in Table 11 (RRA omitted) and Table 12 (RRA performed). 
The odds ratio for SIR increases along with recurrence risk class in both RRA 
treated and not treated groups. The increased frequency of SIR in intermediate- 
and high-risk groups compared with low-risk group reaches statistical 
significance only in the RRA treated group. 
Table 11. Outcome of PTC patients treated with bilateral surgery and not 
submitted to RRA 
 Outcome  
  
 ATA risk of 
recurrence 
Absence of 
SIR 
SIR Total p 
OR  
[95%CI] 
Low 700 (99.3%) 5 (0.7%) 705 ref ref 
Intermediate 132 (98.5) 2 (1.5%) 134 0.31 
2.1188  
[0.1998 - 13.1098] 
High 3 (75%) 1 (25%) 4 0.03 
44.6496  
[0.742 - 700.1687] 
Total 835 (99.1%) 8 (0.9%) 843   
Fisher exact test 
Table 12. Outcome of PTC patients treated with bilateral surgery and RRA 
 Outcome  
  
 ATA risk of 
recurrence 
Absence of 
SIR 
SIR Total p 
OR  
[95%CI] 
Low 583 (99.5%) 3 (0.5%) 586 ref ref 
Intermediate 873 (96.8%) 29 (3.2%) 902 <0.01 
6.4491 
[1.9852 - 33.252] 
High 130 (83.3%) 26 (16.7%) 156 <0.01 
38.6272 
[11.5769 - 202.1478] 
Total 1586 (96.5%) 58 (3.5%) 1644 - - 
Fisher exact test 
3. Follicular thyroid cancer and Hürthle-cell thyroid cancer 
Follicular thyroid cancer presented with SIR after 1 year form primary surgery in 
the 2.2% of the cases: none of the FTC without a precise histopathologic 
classification had SIR, one patients with minimally invasive FTC (FTC MI) and 2 
patients with widely invasive FTC (FTC WI). A tendency to a more frequent SIR in 
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FTC WI compared with FTC MI was observed (OR of 7.6) even though the 
difference was not statistically significant (Table 13).  
Table 13. Outcome of FTC patients 
 Outcome  
  
Histology 
subtypes 
Absence of SIR SIR Total p 
OR  
[95%CI] 
FTC NOS 3 (100%) - 3 - - 
FTC MI 105 (99%) 1 (1%) 106 ref ref 
FTC WI 27 (93.1%) 2 (6.9%) 29 0.11 
7.6176 
[0.3834 - 461.5782] 
Total 135 (97.8%) 3 (2.2%) 138   
Fisher exact test 
Only one over 49 (2%) HCCs had SIR after 1 year from primary surgery. 
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Response to treatment evaluated at 3 years 
The 30% (829 patients) of the cohort had a 3-year disease evaluation available. 
The characteristics of these patients are consistent with those of the original 
cohort and are listed in Table 14. 
Table 14. Characteristics of the study population that reached 3 years of follow up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The outcome at 3 years from primary surgery was ER in 537 (64.8%), BIR in 57 
(6.9%), SIR in 39 (4.7%) and Ind in 196 cases (23.6%).  The rate of SIR at 3 years, 
considered as composite outcome of persistence or recurrence, increased 
significantly along with the initial risk estimate as observed with persistent 
disease at 1 year (Table 15).  
No. patients 829 
Gender - N (%) 
Male  
Female 
 
 
215 (26%) 
711 (74%) 
Age - median (range) 48 (12 - 84) 
Histology - N (%) 
-  Papillary 
-  Follicular  
-  Hürthle  
-  Other (mixed tumors) 
 
771 (93%) 
44 (5.3%) 
13 (1.6%) 
1 (0.1%) 
Tumor size – median (range) 11 (1 - 100) 
Risk of recurrence ATA - N (%)  
- Low 
- Intermediate 
- High 
 
445 (53.7%) 
346 (41.7%) 
38 (4.6%) 
Surgery - N (%) 
- Total/near total thyroidectomy 
- Lobectomy+completion thyroidectomy 
- Lobectomy  
 
821 (99%) 
3 (0.4%) 
5 (0.6%) 
Lymph node dissection - N (%) 
-  No 
- Central compartment 
- Central and lateral compartments 
- Lateral compartments 
 
476 (57.4%) 
272 (32.8%) 
67 (8.1%) 
14 (1.7%) 
Radioiodine remnant ablation/treatment - N (%) 
- Performed 
- Not performed 
 
335 (65.7%) 
494 (34.3%) 
Radioiodine preparation - N (%) 
- rhTSH 
- thyroid hormone withdrawal 
- unknown 
 
145 (44.3%) 
338 (52.3%) 
11 (3.4%) 
Radioiodine activity (mCi) - median (range)  100 (30 - 200) 
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Table 15. Outcome at 3 years  
 Outcome    
 ATA risk of 
recurrence 
Absence of 
SIR 
SIR Total p 
OR  
[95%CI] 
Low 
440 
(98.9%) 
5  
(1.1%) 
445 ref ref 
Intermediate 
319 
(92.2%) 
27  
(7.8%) 
346 <0.01 
7.4304 
[2.7802 – 24.9835] 
High 
31 
(81.6%) 
7  
(18.4%) 
38 <0.01 
19.5482  
[5.0189 - 82.7853] 
Total 790 (95.3%) 39 (4.7%) 829   
Fisher exact test 
The outcome in 4 classes at 3 years according to initial response to treatment 
classification is represented in Table 16. ER status at 1 year was confirmed after 
3 years in 410 (82.8%) over 495 patients. One third of the patients initially 
classified as BIR changed their status as ER and 1/3 as Ind while only the 16.7% 
was confirmed as BIR. Patients with SIR changed their status without any 
treatment in 5 cases (suspicious imaging findings at 1 year not confirmed on 
further assessments), while further treatments (radioiodine, surgery or both) 
were performed in 6 cases. Ind patients remained Ind in 44% of the cases, 
spontaneously achieved ER status in the 38% of the cases, while in about 9% of 
the cases were upstaged to BIR. 
Table 16. Outcome in 4 classes at 3 years according to initial response to 
treatment 
 
Outcome at 3 years 
 
Outcome at 1 
year 
ER BIR SIR Ind Total 
ER 
410  
(82.8%) 
26 (5.3%) 
3  
(0.6%) 
56  
(11.3%) 
495 
BIR 
2  
(33.3%) 
1 
(16.7%) 
1  
(16.7%) 
2  
(33.3%) 
6 
SIR 
7  
(36.8%) 
3 
(15.8%) 
8 
(42.1%) 
1  
(5.3%) 
19 
Ind 
118 
(38.2%) 
27 
(8.7%) 
27 
(8.7%) 
137 
(44.3%) 
309 
Total 537 (64.8%) 57 (6.9%) 39 (4.7%) 196 (23.6%) 829 
 
The rate of SIR found at 3 years increased form the 0.6% in patients initially 
classified as ER (true disease relapse), to 8.7% in patients initially classified as 
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Ind and 16.7% in patients initially classified as BIR.  The 42% of patients who 
had persistent disease at 1 year had SIR in 42% of the cases (Table 17).  
Table 17. Outcome in 4 classes at 3 years according to initial response to 
treatment 
 
Outcome at 3 years 
 
  
Outcome at 1 
year 
Absence of 
SIR 
SIR Total p 
OR  
[95%CI] 
ER 
492 
(99.4%) 
3  
(0.6%) 
495 ref ref 
Ind 
282 
(91.3%) 
27 
(8.7%) 
309 <0.01 
15.6566 
 [4.7537 - 81.327] 
BIR 
5 
(83.3%) 
1  
(16.7%) 
6 
0.05 31.44  
[0.5215 - 482.5554] 
SIR 
11 
(57.9%) 
8 
(42.1%) 
19 
<0.01 112.9494  
[23.4439 - 733.984] 
Total 790 (95.3%) 39 (4.7%) 829   
Fisher exact test 
The outcome according to initial response to treatment classification stratified 
by initial risk estimate is reported in Table 18 panels a, b, c. Overall, the 
probability of spontaneous improvement of the response class was higher for 
low risk patients compared with intermediate and high risk. Both low risk 
patients initially classified as SIR changed their status to ER without any 
treatment, half of BIR and about 40% of Ind were finally classified as ER. On the 
other hand, all true relapses were observed in patients initially classified as 
intermediate risk while none of the low risk patients had disease relapse.  
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Table 18. Outcome at 3 years according to initial response to treatment divided 
for ATA risk of recurrence estimate  
Panel a. Low risk patients 
 3 years Outcome  
1 year Outcome ER BIR SIR Ind Total 
ER 231 (84.3%) 6 (2.3%) - 37 (13.5%) 274 
BIR 1 (50%) - - 1 (50%) 2 
SIR 2 (100%) - - - 2 
Ind 66 (39.5%) 18 (10.8%) 5 (3%) 78 (46.7%) 167 
Total 300 (67.4%) 24 (5.4%) 5 (1.1%) 116 (26.1%) 445 
Panel b. Intermediate risk patients 
 3 years Outcome  
1 year Outcome ER BIR SIR Ind Total 
ER 168 (81.2%) 18 (8.7%) 3 (1.4%) 18 (8.7%) 207 
BIR 1 (25%) 1 (25%) 1 (25%) 1 (25%) 4 
SIR 4 (40%) 1 (10%) 4 (40%) 1 (10%) 10 
Ind 48 (38.4%) 6 (4.8%) 19 (15.2%) 52 (41.6%) 125 
Total 221 (63.9%) 26 (7.5%) 27 (7.8%) 72 (20.8%) 346 
Panel c. High risk patients 
 3 years Outcome  
1 year Outcome ER BIR SIR Ind Total 
ER 11 (78.6%) 2 (14.3%) - 1 (7.1%) 14 
BIR - - - - - 
SIR 1 (14.3%) 2 (28.6%) 4 (57.1%) - 7 
Ind 4 (23.5%) 3 (17.6%) 3 (17.6%) 7 (41.2%)  17 
Total 16 (42.1%) 7 (18.4%) 7 (18.4%) 8 (21.1%)  38 
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miRNA profile analysis: miRNA population  
A subset of 55 PTC patients followed at the Thyroid cancer clinic of University of 
Rome Sapienza and referred to total thyroidectomy was enrolled for the miRNA 
analysis. Sera of eleven patients were used for the screening analysis (screening 
cohort) and 44 for validation analysis (validation cohort) together with 39 age 
and sex matched controls (19 subjects with benign thyroid nodules and 20 
healthy controls).  
Screening Analysis 
Preoperative and postoperative sera (collected 30 days after surgery) of the 
patients of the screening cohort were analyzed and the quantification of 754 
miRNAs was performed. Eleven miRNAs had a significantly lower level in the 
postoperative samples than in the preoperative samples (Table 19). None of the 
754 miRNAs analyzed demonstrated a significantly increased expression 
comparing pre and post-operative samples. 
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Table 19. miRNAs that decreased after surgery in the screening group 
miRNA ID 
Pre-operative  
 samples 
Post-operative  
 samples 
P-value* 
hsa-miR-103a-3p 1(0.473-1.682) 0.121(0.025-0.286) 0.0061 
hsa-miR-222-3p 1(0.310-2.424) 0.390(0.190-0.877) 0.0071 
hsa-miR-24-3p 1(0.282-2.285) 0.379(0.097-0.973) 0.0079 
hsa-miR-28-3p 1(0.057-2.190) 0.253(0.109-0.412) 0.0091 
hsa-miR-191-5p 1(0.125-1.869) 0.350(0.155-0.832) 0.0117 
hsa-miR-146a-5p 1(0.104-2.026) 0.340(0.028-0.711) 0.0129 
hsa-miR-454-3p 1(0.101-2.986) 0.105(0.002-0.265) 0.0205 
hsa-miR-186-5p 1(0.205-2.428) 0.425(0.157-0.908) 0.0288 
hsa-miR-489-3p 1(0.097-2.709) 0.126(0.092-0.194) 0.0333 
hsa-miR-126-3p 1(0.176-2.946) 0.424(0.080-1.086) 0.0356 
hsa-miR-320a 1(0.159-2.004) 0.326(0.074-0.752) 0.0398 
Mann-Whitney test. Results are expressed as RQ (RQ min- RQ max). Post-operative levels are 
normalized to levels found in pre-operative serum samples (equal to 1). 
 
Validation Analysis 
Ten miRNA were selected for validation analysis according to the following 
criteria:  
- 6 miRNA (miRNA-146a-5p, miRNA-28-3p, miRNA-103a-3p, miRNA-222-3p, 
miRNA-191-5p, miRNA-24-3p) that disclosed a marked decline in the expression 
comparing pre and post-operative samples (cut-off of <0.02 vs mean 
preoperative levels)  
- 4 miRNA (miRNA-146b-5p, miRNA-2213p, miRNA-95-3p, miRNA-190a-5p) that 
were found associated with PTC in the literature with high quality evidence(Lee, 
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Zhao et al. 2013, Cancer Genome Atlas Research Network 2014, Graham, Hart et 
al. 2015, Hu, Wang et al. 2016).  
The levels of these 10 miRNAs were analyzed in the sera of 44 PTC (collected pre 
and post-operatively) and those of 39 controls (preoperatively in the 19 subjects 
with benign thyroid nodules and at study enrollment for the 20 healthy controls). 
The level of two miRNAs (miRNA-95-3p and miRNA-190a-5p) was below the 
detection limits of our assay (Ct values higher than 35) and so they were 
excluded from further analysis.  
All the remaining 8 miRNAs levels were less abundant in the postoperative 
samples compared with pre-operative sera (Figure 2). The miRNAs that disclosed 
the most significant decrease were:  miRNA-146a-5p (p 0.0007), miRNA-221-3p 
(p  <0.0001), and miRNA-222-3p (p <0.0001). 
 
 
Figure 2. Validation of 8 miRNA serum levels in 44 patients with PTC 
(preoperative and postoperative samples), 19 controls with benign nodules 
(preoperative sample), and 20 healthy controls (enrollment sample). Data are 
reported as mean copies/mL ± standard deviation; *P <0.05, **P <0.01, and ***P 
<0.001. (Kruskal-Wallis test followed by Dunn’s multiple comparison test for 
intergroup differences; Mann-Whitney test for intraindividual differences.) ns, 
not significant. 
 
Compared with healthy controls, all the 8 miRNAs were significantly more 
abundant in the preoperative sera from the patients with PTC. The preoperative 
expression level of the 8 miRNAs in the PTC patients was not significantly 
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different form that of the patients with benign nodules, although the mean 
serum level of miRNA-221-3p in preoperative samples of PTC patients 
appreciably exceeded that found in samples from patients with benign nodules 
(653,242,460 ± 490,942,066 copies/mL versus 316,148,953 ± 153,115,869 - p = 
0.076).  
Three miRNAs (miRNA-146a-5p, miRNA-221-3p, and miRNA-222-3p) that 
disclosed the most marked decrease in postoperative samples in PTC patients 
were selected for ROC curve analysis.  
The 3 miRNAs demonstrated a good accuracy in discriminating between PTC 
patients and healthy controls (Figure 3, panel A) but a lower performance was 
found in the differentiation of PTC and benign nodules (Figure 2, panel B). Both 
miRNA-146a-5p and miRNA-221-3p had better accuracy in the discrimination of 
PTC than miRNA-222-3p.  
 
 
 
Figure 3. ROC curve analyses to explore the diagnostic value of miRNA-146a5p, 
miRNA-221-3p, and miRNA-222-3p levels for discriminating (A) between PTC 
patients and healthy controls and (B) between PTC patients and patients with 
benign nodules. Tables on the right show areas under the curve (AUC) with 95% 
confidence intervals (95% CI) and cutoffs (indicated on curves as solid black 
circles and reported as copies per milliliter) with associated sensitivity and 
specificity. BN: benign nodules; HC: healthy controls. 
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Follow up analysis  
The levels of miRNA-146a-5p and miRNA-221-3p were analyzed in additional 
serum samples collected at the moment of first follow up disease assessment 
(performed 12-24 months from primary surgery i.e. follow up sample) from 20 
of the 44 PTC patients (from whom samples were available) (Figure 4). The 
response to treatment was ER or Ind in 15 (75%) of the patients, BIR in one 
patient (5%) and SIR in 4 (20%).  The expression levels of miRNA-146a-5p and 
miRNA-221-3p decreased in the postoperative samples and remained low in the 
follow up sample in the 15 ER patients and in the BIR patient.  On the other hand, 
in the 4 SIR patients the levels of expression of miRNA-146a-5p and miRNA-221-
3p increased in the follow up sample to levels comparable or higher to the 
preoperative ones.   
Serum Tg levels evaluated in these 20 PTC patients at 1 months and 12-24 
months after primary surgery were consistent with clinical findings and with 
circulating levels of the 2 miRNAs in 17 cases.  
Three patients, initially treated with total thyroidectomy not followed by RRA, 
were better defined by miRNA profile than conventional thyroid cancer markers. 
In one patient (case 1) a rising trend of Tg (from 0.17 ng/mL to 0.95 ng/mL) and 
a declining trend of TgAbs (from 61.4 IU/mL to 14.3 IU/mL) with stable TSH levels 
was observed, neck ultrasound revealed no evidence of structural disease; the 
trend of the two miRNAs analyzed was declining.  Two cases had evidence of 
structural disease on neck US (suspicious lymph nodes) and declining trend of 
serum Tg (from 0.7 and 0.36 ng/mL to 0.11 and 0.15 ng/mL respectively) and of 
TgAbs (case 2 and 3). In both cases the levels of miRNA-146a-5p and miRNA-221-
3p were found more abundant in the follow up sample.  
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Figure 4. Levels of miRNA-146a, miRNA-221-3p, and Tg in preoperative and 
postoperative (1 month and 12-24 months) serum samples of PTC patients 
classified according to response to treatment classes. Case 1: Patient with an 
indeterminate response and increasing serum Tg levels. Cases 2 and 3: Patients 
with structural incomplete responses and decreasing serum Tg levels (less than 
1 ng/mL). 
 
Discussion 
Our data demonstrates that the risk stratification system proposed by the ATA 
is effective in predicting the risk of persistent disease evaluated at about 1 year 
from primary surgery. It has also shown a good prediction of the composite 
outcome (persistent/recurrent disease) at about 3 years from primary surgery. 
The miRNA profiling analysis demonstrated that the trend of miRNA-146a-5p 
and miRNA-221-3p is a promising tool for disease assessment of PTC patients.  
This study has several limitations. Complete information on pathology was used 
as an inclusion criterion but some details on lymph node pathologic features (e.g. 
metastasis size, extra-nodal invasion) that may have an important prognostic 
role in risk stratification (Randolph, Duh et al. 2012) were not available for all 
patients. Also, data on molecular characterization of the tumors are lacking. 
Even if relevant prognostic information is provided by molecular 
characterization of thyroid tumors (Cancer Genome Atlas Research Network 
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2014, Fagin and Wells 2016), this kind of analysis is not offered by the public 
health system in Italy and is performed with research purpose in some referral 
centers. Like other multicentric studies, heterogenous disease assessment 
methods were used in each ITCO center.  Serum biomarkers were not centralized 
in the same laboratory and several assays with different functional sensitivities 
were employed with potential bias in response to treatment result assessment. 
For this reason, the outcome was also evaluated as presence and absence of SIR 
that is defined only by imaging studies results, avoiding the influence serum 
biomarkers variability. Neck ultrasound was the imaging tool employed in almost 
all patients, but it is an operator dependent technique with high interobserver 
variability (Grani, Lamartina et al. 2018). This limit may be partly overcome by 
the use of scoring systems (Grani, Lamartina et al. 2018) as the one proposed by 
the European Thyroid Association for the classification of neck lymph nodes and 
thyroid bed nodules (Leenhardt, Erdogan et al. 2013, Lamartina, Grani et al. 
2016) that was adopted in the ITCO database to standardize ultrasound reports. 
From another point of view, these limitations reflect the clinical clues faced by 
clinicians in the real-life setting.   
Some subgroups, namely FTC and HCC, were too small and the number of events 
too low for robust statistical analysis. This histotypes represent only the 6% of 
all DTCs in contemporary series (Lamartina, Durante et al. 2017). Most of the 
evidence available on these tumors relies on small series or larger retrospective 
series of cohorts diagnosed during a very long time period (up to the 50s-70s). 
During the same period, the pathologic criteria for FTCs and HCCs have changed 
several times (Tallini, Tuttle et al. 2017). The information available on these 
histotypes remains limited (Grani, Lamartina et al. 2017).  
As for PTCs the number of subjects enrolled was not negligible. Nevertheless, 
non-RRA treated PTC patients (representing about 1/3 of the population) only a 
tendency to significant prediction of SIR by the ATA risk stratification system was 
observed. It is worth note that patients who were not submitted to RRA were 
more likely to be low risk. Therefore, a larger population is probably needed to 
provide more statistically robust results in this subgroup.  
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The observational design precludes to draw conclusions on the influence of the 
kind of treatment performed and patient outcome. On the other hand, a picture 
of clinical choices made in thyroid cancer treatment in the ITCO Italian centers is 
provided. Bilateral thyroid surgery is performed in the vast majority (97.8%) of 
patients often together with lymph node surgery (40% of the patients). More 
limited surgery is performed only in a limited number of low and intermediate 
risk patients. This attitude might reflect some inertia in the adoption of most 
recent guideline recommendations (Lamartina, Durante et al. 2017) but also the 
high prevalence of bilateral nodular thyroid disease may have played a role 
(Durante, Costante et al. 2015).  The use of RRA is more selective and appears 
guided by the risk of recurrence evaluated at the moment of diagnosis 
(Lamartina, Durante et al. 2017).  Still, a high proportion of low risk patients 
(46%) is treated regardless their excellent prognosis: only the 0.6% had 
persistent disease at the 1-year assessment and none experienced disease 
recurrence.    
Only 3 patients experienced recurrent disease at 3 years form primary surgery. 
A short follow up period was considered, and some disease recurrences may 
become evident later during follow up. Thyroid cancer relapses have been 
described to occur up to 20-40 years form diagnosis (Mazzaferri and Jhiang 
1994). This study reflects an era where therapeutic and diagnostic tools where 
much different from those available now days (Lamartina, Deandreis et al. 2016, 
Lamartina, Grani et al. 2018). More recent series of PTC patients, followed with 
neck ultrasound and sensitive thyroglobulin assays, have shown that true 
relapses are rare (1.4%) and occur early after diagnosis (Durante, Montesano et 
al. 2013). More than a half of these recurrences are observed within 3 years from 
diagnosis (Durante, Montesano et al. 2013).  
Overall the rates of persistent disease observed in this large and prospective 
cohort are low (2.6%) and the most frequent response category at 1 year was 
excellent response (about two thirds of the population). The rate of true 
recurrences was only 0.6% and none of the low risk patients experienced 
recurrence. Aggressive treatment and follow-up protocols are probably not 
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justified in these patients that represent the vast majority of DTC patients. 
Roughly one third of the patients had an indeterminate response at the 1-year 
assessment. As described in other studies (Lamartina, Montesano et al. 2016), a 
good number of the patients (38%) with indeterminate response will 
spontaneously achieve excellent response later during follow up. Less than 10% 
will develop SIR, the likelihood of SIR in patients initially classified as 
indeterminate response grew with recurrence risk class: 3% in low risk patients, 
15.2% in intermediate risk patients and 17.6% in high risk patients. Still the need 
for biomarkers alternative to thyroglobulin, such as miRNAs, is therefore of great 
interest.   
The miRNA profile analysis was performed in a small subgroup of patients and 
further validation on larger cohorts is needed. Nonetheless, a rigorous 
methodology of analysis was employed on a well characterized longitudinal 
population (Rosignolo, Sponziello et al. 2017). The kits used RNA isolation 
(miRNeasy Serum/Plasma kit, Qiagen), allowed the detection of low-abundance 
miRNAs and the isolation of more concentrated RNA samples than other kits of 
this type (Farina, Wood et al. 2014). The multiple-extraction approach allowed 
us to obtain over 1,000 ng total RNA from each serum sample, thereby 
eliminating the need for cDNA preamplification (that is a potential source of 
technical bias). Reliable endogenous controls for circulating miRNA analysis are 
lacking (Farina, Wood et al. 2014), to overcome this problem absolute 
quantitative polymerase chain reaction was used for all the analyses performed 
in the validation cohort. miRNA levels were consistent with serum thyroglobulin 
in all but three cases. In these cases, miRNA profile reflected the actual patient 
status better than serum thyroglobulin.  
In conclusion the analysis of miRNA profiles could represent a valuable 
biomarker for early definition of the disease status namely in those cases in 
which traditional markers are less informative.  
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